Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (DE:EXK)
FRANKFURT:EXK
EXK Stock Chart & Stats
€86.54
-€1.13(-2.05%)
At close: 4:00 PM EST
€86.54
-€1.13(-2.05%)
Day’s Range― - ―
52-Week Range€33.80 - €88.16
Previous CloseN/A
Volume60.00
Average Volume (3M)3.00
Market Cap
€16.60B
Enterprise Value€21.17B
Total Cash (Recent Filing)€964.71M
Total Debt (Recent Filing)€2.52B
Price to Earnings (P/E)―
Beta-0.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding190,810,200
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)7.98
Price to Sales (P/S)5.90
P/FCF Ratio53.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€87.25Price Target Upside0.82% Upside
Rating ConsensusHold
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition Premium And Shareholder ValueABT's offer of $105 per share represents a substantial premium to pre-deal prices, delivering clear value realization for Exact Sciences shareholders.
Commercial Momentum And Product PipelineReaccelerated Cologuard screening volumes, early CMS coverage for Oncodetect, and a leading MRD pipeline position the business to capture significant share in the expanding cancer diagnostics market.
Strategic Expansion Into Oncology DiagnosticsThe acquisition adds a major oncology diagnostics vertical and is expected to expand the combined company's total addressable market by more than forty billion dollars, creating new growth opportunities.
Bears Say
Deal Size Deters Competing BidsThe large transaction value and scale of the deal reduce the likelihood of a higher competing bidder emerging, capping the chance of a takeover-driven price increase.
Limited Upside For Remaining InvestorsShares trading at or near the proposed acquisition price significantly limit upside potential, prompting analyst downgrades to hold or neutral.
Near-term Dilution And Integration RiskAnalysts flag expected dilution in 2026 and 2027 and potential integration challenges as factors that could pressure near-term earnings and execution for the combined company.
Exact Sciences News
EXK FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was €33.80 and its highest was €88.16 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is €16.60B.
When is Exact Sciences Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Exact Sciences Corp.’s earnings last quarter?
Currently, no data Available
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 190,810,200 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in DE:EXK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€87.25 (0.82% Upside)
€87.25 (0.82% Upside)
Blogger Sentiment
Bullish
DE:EXK Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.56%
12-Months-Change
Fundamentals
Return on Equity
-34.54%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXK Company Deck
EXK Earnings Call
Q3 2025
0:00 / 0:00
EXK Stock 12 Month Forecast
Average Price Target
€87.25
▲(0.82% Upside)
Technical Analysis
Options Prices
Currently, No data available
---